| Name | Title | Contact Details |
|---|
We are an OEM manufacturer of linear actuators and lifting columns, located in the Greater Grand Rapids area! Our parents company, Jiecang Linear Motion Technology Co.,Ltd was established in 2000 in Xinchang, China. Due to their high standards, their products quickly became globally respected for use in medical and home care equipment. With a large customer base in the United States, they found it necessary to purchase a facility locally which happened in 2018.
The Big Biscuit, founded in 2000, is an All-American breakfast and lunch concept focusing on freshly prepared classic comfort food consistently served with generous portions in a family-friendly environment. The Big Biscuit has 27+ locations in Kansas, Missouri, Oklahoma, and Arkansas
Stellar is a manufacturer and distributor of domestic hydraulic hook-lift hoist and accessories.
Safe & Green Holdings Corp., a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various industries. The firm supports third party and in-house developers, architects, builders and owners in achieving faster execution, greener construction, and buildings of higher value. SGH Corp. products have been featured in several media outlets including Fortune, NY Times, NY Post, USA Today, CNN, Washington Post and more. The company has completed projects for: US Army and Navy, US Department of Veteran Affairs, The City of Santa Monica, Port of Houston Authority, Aman Resorts, BareBurger, Equinox, HGTV, Lacoste, Marriott Hotels & Resorts, Mini Cooper, Starbucks and more.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.